GUIDED THERAPEUTICS INC Quarterly Debt-to-equity in % from Q3 2019 to Q2 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Guided Therapeutics Inc quarterly Debt-to-equity history and growth rate from Q3 2019 to Q2 2025.
  • Guided Therapeutics Inc Debt-to-equity for the quarter ending June 30, 2025 was -122 %, a 12% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2025 -122 +16.7 +12% Jun 30, 2025
Q1 2025 -125 +25.1 +16.8% Mar 31, 2025
Q4 2024 -129 +35.4 +21.5% Dec 31, 2024
Q3 2024 -133 +50 +27.4% Sep 30, 2024
Q2 2024 -139 +67.6 +32.7% Jun 30, 2024
Q1 2024 -150 +32.2 +17.7% Mar 31, 2024
Q4 2023 -164 +2.61 +1.56% Dec 31, 2023
Q3 2023 -183 -31.6 -20.9% Sep 30, 2023
Q2 2023 -207 -86.5 -72.1% Jun 30, 2023
Q1 2023 -182 -71.9 -65.1% Mar 31, 2023
Q4 2022 -167 -57.4 -52.4% Dec 31, 2022
Q3 2022 -151 -44.8 -42.2% Sep 30, 2022
Q2 2022 -120 -9.37 -8.46% Jun 30, 2022
Q1 2022 -110 +1.68 +1.5% Mar 31, 2022
Q4 2021 -110 -2.12 -1.97% Dec 31, 2021
Q3 2021 -106 +0.31 +0.29% Sep 30, 2021
Q2 2021 -111 -6.2 -5.93% Jun 30, 2021
Q1 2021 -112 -8.71 -8.43% Mar 31, 2021
Q4 2020 -108 -4.41 -4.28% Dec 31, 2020
Q3 2020 -106 -4.66 -4.58% Sep 30, 2020
Q2 2020 -105 Jun 30, 2020
Q1 2020 -103 Mar 31, 2020
Q4 2019 -103 Dec 31, 2019
Q3 2019 -102 Sep 30, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.